BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Charles S. Swindell Joins Phyton, Inc. As Vice President Of Research And Development


10/19/2005 5:12:26 PM

FORT WORTH, Texas and ITHACA, N.Y., Dec. 13 /PRNewswire/ -- Magnus Precht, President of Phyton Biotech, Inc., a DFB Pharmaceuticals affiliate, has announced hiring Charles S. Swindell, Ph.D. as Vice President of Research and Development.

Based in Ithaca, New York, Phyton Biotech, Inc. is a world leader in the use of plant cell culture technology, a platform used to develop and manufacture products with applications in the pharmaceutical and biotech industries. Phyton currently generates revenue by efficiently producing a commercial source of paclitaxel, the active ingredient in Taxol(R)*, one of the leading drugs for the treatment of cancer. Its German subsidiary, Phyton Gesellschaft fur BiotechnikmbH, operates the world's largest commercial cGMP manufacturing facility using plant cell culture technology.

"We're pleased to have Dr. Swindell join our talented Phyton team," Mr. Precht said. "Dr. Swindell will head up all R&D activities related to plant cell culture technology and broaden our drug development capability. We are in an enviable position to have the inventor of a patented paclitaxel manufacturing process leading our team."

Mr. Precht added that Dr. Swindell will play a key role in further developing Phyton as a fully-integrated biotechnology company with a complete range of capabilities from R&D through manufacturing and marketing.

"I am delighted to have the opportunity to join the Phyton Biotech management team," said Dr. Swindell. "Having been involved in paclitaxel research for twenty-five years, I had the opportunity to watch the impressive work of the Phyton scientists that made plant cell culture-derived paclitaxel available to cancer patients. Now it is exciting to be able to play a personal role in the extension of Phyton's technology to the development and manufacture of additional pharmaceutical products."

Dr. Swindell has extensive experience in the biotech industry. He served as Senior Vice President of Research and Development for a Philadelphia area biopharmaceutical company, Protarga, Inc. There, he built the research and development organization, which advanced the company's first drug in clinical development from US Phase I through international Phase II and on to pivotal Phase III clinical studies. He also established and managed collaborations with the US National Cancer Institute and other academic, governmental and corporate partners.

Dr. Swindell chaired the Department of Chemistry at Bryn Mawr College, where he was a member of the faculty for nearly two decades, rising to the rank of full Professor. He led an internationally-recognized National Institutes of Health-funded academic research program focused on the chemistry of taxane drugs. While at Bryn Mawr, he invented and licensed a patented paclitaxel manufacturing process.

Charles Swindell received a BS in chemistry from the University of Houston (Texas) in 1974. He then earned a Ph.D. in organic chemistry from Rice University in Houston in 1980. Dr. Swindell was a Swiss National Science Foundation Postdoctoral Fellow at the ETH-Zurich in Zurich, Switzerland.

His professional involvement includes memberships in the American Chemical Society and the American Society of Pharmacognosy. Dr. Swindell served as an editorial board member for the Journal of Lipid Research for almost a decade. He has been a contributor to and author of numerous scholarly articles, book chapters, and presentations. He and his teams have received research grants and contract awards from the National Science Foundation and the National Cancer Institute, among others.

Phyton Biotech, Inc. is a subsidiary of DFB Pharmaceuticals Inc. and has facilities in Ithaca, New York, and Ahrensburg, Germany. Phyton's proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries. Its German subsidiary, Phyton GmbH, operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation.

DFB Pharmaceuticals Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities to the healthcare industry worldwide through its affiliates, HEALTHPOINT, Ltd., a branded marketing organization and DPT Laboratories, Ltd., an outsourcing service organization to the pharmaceutical industry. Visit http://www.dfb.com/ for additional information.

* Taxol is a registered trademark of Bristol Myers Squibb Company.

Phyton Biotech, Inc.

CONTACT: Magnus Precht of Phyton Biotech, Inc., +1-800-441-8227, ormagnus.precht@phytonbiotech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->